Soleno Therapeutics Stock Performance
| SLNO Stock | USD 37.24 1.39 3.60% |
The entity has a beta of 1.34, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Soleno Therapeutics will likely underperform. At this point, Soleno Therapeutics has a negative expected return of -0.33%. Please make sure to validate Soleno Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Soleno Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Soleno Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (3.60) | Five Day Return (10.37) | Year To Date Return (21.05) | Ten Year Return (91.99) | All Time Return (97.44) |
Last Split Factor 1:15 | Dividend Date 2017-10-06 | Last Split Date 2022-08-26 |
1 | Soleno Therapeutics Reports Strong Q3 Earnings Despite VYKAT XR Safety Concerns | 11/25/2025 |
2 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO | 01/08/2026 |
3 | Acquisition by Anish Bhatnagar of 131400 shares of Soleno Therapeutics at 43.65 subject to Rule 16b-3 | 01/21/2026 |
4 | Soleno Therapeutics Inc. Analysts See Major Upside | 01/23/2026 |
5 | Solena Therapeutics Stock Under Pressure But Upside is Huge | 01/27/2026 |
6 | FDA Accepts SMMTs Application Seeking Approval for NSCLC Drug | 01/30/2026 |
7 | A Look At Soleno Therapeutics Valuation As VYKAT XR Launch Shapes A Transformational 2025 | 02/03/2026 |
8 | What Soleno Therapeutics s VYKAT XR Momentum and 2025 Outlook Could Mean For Shareholders | 02/05/2026 |
9 | Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 430 PM ET | 02/11/2026 |
| Begin Period Cash Flow | 169.7 M | |
| Total Cashflows From Investing Activities | -225.7 M |
Soleno Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,725 in Soleno Therapeutics on November 17, 2025 and sell it today you would lose (1,001) from holding Soleno Therapeutics or give up 21.19% of portfolio value over 90 days. Soleno Therapeutics is currently does not generate positive expected returns and assumes 3.2107% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Soleno, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Soleno Therapeutics Target Price Odds to finish over Current Price
The tendency of Soleno Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 37.24 | 90 days | 37.24 | about 99.0 |
Based on a normal probability distribution, the odds of Soleno Therapeutics to move above the current price in 90 days from now is about 99.0 (This Soleno Therapeutics probability density function shows the probability of Soleno Stock to fall within a particular range of prices over 90 days) .
Soleno Therapeutics Price Density |
| Price |
Predictive Modules for Soleno Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Soleno Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Soleno Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Soleno Therapeutics is not an exception. The market had few large corrections towards the Soleno Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Soleno Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Soleno Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.37 | |
β | Beta against Dow Jones | 1.34 | |
σ | Overall volatility | 3.80 | |
Ir | Information ratio | -0.11 |
Soleno Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Soleno Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Soleno Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Soleno Therapeutics generated a negative expected return over the last 90 days | |
| Soleno Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (175.85 M) with profit before overhead, payroll, taxes, and interest of 96.84 M. | |
| Soleno Therapeutics currently holds about 24.07 M in cash with (69.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97. | |
| Soleno Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 430 PM ET |
Soleno Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Soleno Stock often depends not only on the future outlook of the current and potential Soleno Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Soleno Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.2 M | |
| Cash And Short Term Investments | 291.4 M |
Soleno Therapeutics Fundamentals Growth
Soleno Stock prices reflect investors' perceptions of the future prospects and financial health of Soleno Therapeutics, and Soleno Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Soleno Stock performance.
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 1.55 B | ||||
| Shares Outstanding | 53.71 M | ||||
| Price To Earning | (3.71) X | ||||
| Price To Book | 4.04 X | ||||
| Price To Sales | 20.27 X | ||||
| Gross Profit | 96.84 M | ||||
| EBITDA | (173.63 M) | ||||
| Net Income | (175.85 M) | ||||
| Cash And Equivalents | 24.07 M | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 52.83 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.43 X | ||||
| Book Value Per Share | 9.21 X | ||||
| Cash Flow From Operations | (69.1 M) | ||||
| Earnings Per Share | (1.75) X | ||||
| Market Capitalization | 2 B | ||||
| Total Asset | 330.97 M | ||||
| Retained Earnings | (452.26 M) | ||||
| Working Capital | 275.14 M | ||||
About Soleno Therapeutics Performance
By examining Soleno Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Soleno Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Soleno Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 183.66 | 174.48 | |
| Return On Tangible Assets | (0.49) | (0.51) | |
| Return On Capital Employed | (0.69) | (0.73) | |
| Return On Assets | (0.48) | (0.50) | |
| Return On Equity | (0.83) | (0.87) |
Things to note about Soleno Therapeutics performance evaluation
Checking the ongoing alerts about Soleno Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Soleno Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Soleno Therapeutics generated a negative expected return over the last 90 days | |
| Soleno Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (175.85 M) with profit before overhead, payroll, taxes, and interest of 96.84 M. | |
| Soleno Therapeutics currently holds about 24.07 M in cash with (69.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.97. | |
| Soleno Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 430 PM ET |
- Analyzing Soleno Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Soleno Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Soleno Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Soleno Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Soleno Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Soleno Therapeutics' stock. These opinions can provide insight into Soleno Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Will Biotechnology sector continue expanding? Could Soleno diversify its offerings? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Soleno Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Soleno Therapeutics requires distinguishing between market price and book value, where the latter reflects Soleno's accounting equity. The concept of intrinsic value - what Soleno Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Soleno Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Soleno Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.